测量不可测量之物:自动化骨扫描指数作为前列腺癌临床试验中的定量终点
本文综述自动化骨扫描指数(aBSI)作为转移性去势抵抗性前列腺癌(mCRPC)临床试验定量终点的价值。aBSI与人工BSI及观察者间一致性均>0.95;3期评估中aBSI倍增使死亡风险增加20%,治疗前aBSI独立相关于总生存和症状进展时间。结论认为aBSI可行、可重复,支持用于风险分层,未来需研究其变化作为中间终点。
要点
- aBSI与人工BSI及观察者间一致性均>0.95,可重复性高。
- 3期评估中aBSI倍增使死亡风险增加20%,治疗前aBSI独立相关于总生存和症状进展时间。
- 回顾性研究提示治疗后aBSI下降可能与更高生存相关,但需未来研究验证其作为中间终点。
核心结论
- aBSI提供了一种可行、可重复的定量测量,迄今为止的分析显示其与总生存和症状进展相关。
- 这些发现支持aBSI用于对mCRPC男性进行风险分层以纳入临床试验。
- 未来需要开展量化aBSI随时间变化作为评估新全身治疗的中间终点研究。
研究设计与样本
- 本文为综述,采用手工检索文献的方法识别关于BSI和aBSI的文献。
- 总结了评估aBSI测量的回顾性和前瞻性研究中最相关的内容,并对aBSI的潜在优势和注意事项进行了批判性讨论。
主要发现
- 开发神经网络(EXINI boneBSI)自动确定BSI,减少了评估BSI的周转时间,具有高可重复性和准确性。
- 多项研究显示aBSI与BSI之间的一致性以及aBSI的观察者间一致性均>0.95。
- 在一项aBSI的3期评估中,aBSI倍增使死亡风险增加20%。
- 治疗前aBSI值独立相关于总生存(OS)和症状进展时间。
- 回顾性研究提示,与aBSI升高相比,治疗后aBSI下降可能与更高生存相关。
关键数值与推荐
- aBSI与BSI之间的一致性以及aBSI的观察者间一致性均>0.95。
- 3期评估中aBSI倍增使死亡风险增加20%。
临床怎么用
- 原文结论支持aBSI用于对mCRPC男性进行风险分层以纳入临床试验。
- 原文未据此给出其他临床推荐。
局限性
- 未来需要开展量化aBSI随时间变化作为评估新全身治疗的中间终点研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Up to 90% of men with metastatic castration-resistant prostate cancer (mCRPC) will have a distribution of disease that includes bone metastases demonstrated on a Technetium-99m (99mTc-MDP) bone scan. The Prostate Cancer Working Group 2 and 3 Consensus Criteria standardized the criteria for assessing progression based on the development of new lesions. These criteria have been recognized by regulatory authorities for drug approval. The bone scan index (BSI) is a method to quantitatively measure the burden of bony disease, and can assess both disease progression and regression. The automated BSI (aBSI) is a method of computer analysis to assess BSI, and is being qualified as a clinical trials endpoint. METHODS: Manual searching was used to identify the literature on BSI and aBSI. We summarize the most relevant aspects of the retrospective and prospective studies evaluating aBSI measurements, and provide a critical discussion on the potential advantages and caveats of aBSI. RESULTS: The development of neural artificial networks (EXINI boneBSI) to automatically determine the BSI reduces the turnaround time for assessing BSI with high reproducibility and accuracy. Several studies showed that the concordance between aBSI and BSI, as well as the interobserver concordance of aBSI, was >0.95. In a phase 3 assessment of aBSI, a doubling value increased the risk of death in 20%, pre-treatment aBSI values independently correlated with overall survival (OS) and time to symptomatic progression. Retrospective studies suggest that a decrease in aBSI after treatment may correlate with higher survival when compared with increasing aBSI. CONCLUSIONS: aBSI provides a quantitative measurement that is feasible, reproducible, and in analyses to date correlates with OS and symptomatic progression. These findings support the aBSI to risk-stratify men with mCRPC for clinical trial enrollment. Future studies quantifying aBSI change over time as an intermediate endpoint for evaluating new systemic therapies are needed.
引用
- Mota JM, Armstrong AJ, Larson SM, et al. Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. Prostate Cancer Prostatic Dis. 2019. PMID: 31036925. doi:10.1038/s41391-019-0151-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。